Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Genes & Development

• Publication date

  2006-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/GAD.1417406PMID 16705038PMCID PMC1475762
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

  2006cited by this paper
• K-ras activation generates an inflammatory response in lung tumors

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

  2006cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• Tumour biology: Senescence in premalignant tumours

  2005cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

  2005influential reference
• Identification of bronchioalveolar stem cells in normal lung and lung cancer.

  2005influential reference
• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005influential reference
• The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

  2005cited by this paper
• Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

  2005cited by this paper
• Oncogenes come of age.

  2005influential reference
• Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

  2005cited by this paper
• EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

  2005cited by this paper
• Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

  2005cited by this paper
• The transcriptional repressor Snail promotes mammary tumor recurrence.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

  2005cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255

  2004influential reference
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004influential reference
• Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.

  2004cited by this paper
• Advances in Brief Gefitinib Induces Apoptosis in the EGFRL 858 R Non – Small-Cell Lung Cancer Cell Line H 3255

  2004cited by this paper
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

  2004cited by this paper
• Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

  2004cited by this paper
• High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan

  2004cited by this paper
• Reversibility of oncogene-induced cancer.

  2004influential reference
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

  2003cited by this paper
• Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis.

  2003cited by this paper
• The dark side of Ras: regulation of apoptosis

  2003cited by this paper
• Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor*

  2002cited by this paper
• Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.

  2002cited by this paper
• Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

  2001cited by this paper
• Somatic activation of the K-ras oncogene causes early onset lung cancer in mice

  2001cited by this paper
• Conditional Expression of Fibroblast Growth Factor-7 in the Developing and Mature Lung*

  2000cited by this paper
• Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis.

  2000cited by this paper
• Histological Typing of Lung and Pleural Tumours

  1999cited by this paper
• Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

  1999influential reference
• Bronchioloalveolar carcinoma.

  1996cited by this paper
• Tumor spectrum analysis in p53-mutant mice.

  1994cited by this paper
• Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.

  1992cited by this paper
• Bronchioloalveolar carcinoma.

  1987cited by this paper
• Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.

  1987cited by this paper

• Lung Cancer in Young Adults

  2025cites this paper
• EED Maintains the Small Cell Lung Cancer Neuroendocrine Phenotype and Drives Lung Cancer Histological Transformation

  2025cites this paper
• RIT1 Drives Oncogenic Transformation and is an Actionable Target in Lung Adenocarcinoma.

  2025cites this paper
• An Agrin–YAP/TAZ Rigidity Sensing Module Drives EGFR‐Addicted Lung Tumorigenesis

  2025cites this paper
• Orthotopically Implanted Murine Lung Adenocarcinoma Cell Lines for Preclinical Investigations

  2025cites this paper
• Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state

  2025cites this paper
• Murine models of lung adenocarcinoma: Valuable tools for preclinical investigation.

  2025cites this paper
• Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity

  2025cites this paper
• Conformational Dynamics of Wild‐Type to Triple Mutant EGFR‐TKD Captured by Coarse‐Grained Simulations

  2025cites this paper
• ZDHHC11-mediated AXL palmitoylation promotes osimertinib resistance in non-small-cell lung cancer

  2025cites this paper
• Applications and Complementarity of Organ‐Chips and Animal Models in Lung Cancer Driver Gene Research

  2025cites this paper
• MET Activation in Lung Cancer and Response to Targeted Therapies

  2025cites this paper
• Distinct characteristics of brain metastasis in lung adenocarcinoma: development of high-confidence cell lines

  2025cites this paper
• Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma

  2025cites this paper
• An agent-based modelling framework to study growth mechanisms in EGFR-L858R mutant cell alveolar type II cells

  2024cites this paper
• Beyond genetics: driving cancer with the tumour microenvironment behind the wheel

  2024cites this paper
• Conformational Transitions in EGFR Protein Tyrosine Kinase Domain and Their Modulation by Mutants

  2024cites this paper
• Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies

  2024cites this paper
• Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review

  2024cites this paper
• EGFR-driven lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth.

  2024cites this paper
• In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy.

  2024cites this paper
• How far have we come in our efforts to apply personalized therapy for lung cancer at bedside?

  2024cites this paper
• USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy

  2024cites this paper
• A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression.

  2024cites this paper
• Combinatorial prediction of therapeutic perturbations using causally-inspired neural networks

  2024cites this paper
• DUSP22 inhibits lung tumorigenesis by suppression of EGFR/c-Met signaling

  2024cites this paper
• Preclinical Models for Functional Precision Lung Cancer Research

  2024cites this paper
• The Evolution of Mouse Models of Cancer: Past, Present, and Future.

  2024cites this paper
• Genetically-engineered mouse models of small cell lung cancer: the next generation

  2024cites this paper
• PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy

  2024cites this paper
• Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

  2024cites this paper
• An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1

  2023cites this paper
• FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung.

  2023cites this paper
• IFNγ blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins

  2023cites this paper
• Molecular pathology of non‐small cell carcinoma

  2023cites this paper
• Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells.

  2023cites this paper
• Lung adenocarcinoma promotion by air pollutants

  2023cites this paper
• Footprints: Stamping hallmarks of lung cancer with patient-derived models, from molecular mechanisms to clinical translation

  2023influential citation
• RBM10 loss promotes EGFR-driven lung cancer and confers sensitivity to spliceosome inhibition.

  2023cites this paper
• Transgelin promotes lung cancer progression via activation of cancer-associated fibroblasts with enhanced IL-6 release

  2023cites this paper
• Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention

  2023cites this paper
• Oncogenic context shapes the fitness landscape of tumor suppression

  2023cites this paper
• The Interplay between Dysregulated Metabolism and Epigenetics in Cancer

  2023cites this paper
• The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

  2023cites this paper
• How CRISPR Is Revolutionizing the Generation of New Models for Cancer Research.

  2023cites this paper
• Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse.

  2023cites this paper
• Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression

  2023cites this paper
• The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures

  2023cites this paper
• Lineage-specific intolerance to oncogenic drivers restricts histological transformation

  2023cites this paper
• Cellular Origins and Lineage Plasticity in Cancer.

  2023cites this paper
• IL-6 mediates suppression of T and NK cells function in EMT-associated TKI-resistant EGFR mutant NSCLC<.

  2023cites this paper
• Stearoyl-CoA Desaturase-1 dependent lipid droplets accumulation in cancer-associated fibroblasts facilitates the progression of lung cancer

  2022cites this paper
• Histologic transformation in lung cancer: when one door shuts, another opens

  2022cites this paper
• Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response

  2022cites this paper
• EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer

  2022cites this paper
• Therapeutic targeting of macrophage plasticity remodels the tumor-immune microenvironment.

  2022cites this paper
• Ligand-independent integrin β1 signaling supports lung adenocarcinoma development

  2022cites this paper
• Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation

  2022cites this paper
• Micro-CT acquisition and image processing to track and characterize pulmonary nodules in mice

  2022cites this paper
• Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis

  2022cites this paper
• Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.

  2022cites this paper
• Lung Adenocarcinoma Promotion by 1 Air Pollutants 2

  2022cites this paper
• Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer

  2022cites this paper
• EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer

  2022influential citation
• Retinoblastoma Protein Paralogs and Tumor Suppression

  2022cites this paper
• Non-Small-Cell Lung Cancer Promotion by Air Pollutants

  2022cites this paper
• Do inhibitors targeted against mutant oncogenic kinases act via kinase degradation-induced immune activation?

  2021cites this paper
• A small-molecule compound D6 overcomes EGFR-T790M-mediated resistance in non-small cell lung cancer

  2021cites this paper
• Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer

  2021cites this paper
• Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids

  2021cites this paper
• Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

  2021cites this paper
• Harnessing the predictive power of preclinical models for oncology drug development

  2021cites this paper
• Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy

  2021cites this paper
• Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development.

  2021cites this paper
• A role for club cells in smoking-associated lung adenocarcinoma

  2021cites this paper
• Capturing cancer evolution using genetically engineered mouse models (GEMMs).

  2021cites this paper
• Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma

  2021cites this paper
• EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

  2021cites this paper
• Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer.

  2021cites this paper
• HIF‐1α is necessary for activation and tumour‐promotion effect of cancer‐associated fibroblasts in lung cancer

  2021cites this paper
• Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity.

  2021cites this paper
• Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

  2021cites this paper
• Structural basis of the effect of activating mutations on the EGF receptor

  2021cites this paper
• High expression of MCM10 is predictive of poor outcomes in lung adenocarcinoma

  2021cites this paper
• De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma

  2020cites this paper
• Cells of origin of lung cancers: lessons from mouse studies

  2020influential citation
• Animal models and in vivo investigations for drug repurposing in lung cancer

  2020cites this paper
• The duality of human oncoproteins: drivers of cancer and congenital disorders

  2020cites this paper
• Expression of CHPF modulates cell proliferation and invasion in lung cancer

  2020cites this paper
• CD109 regulates in vivo tumor invasion in lung adenocarcinoma through TGF‐β signaling

  2020cites this paper
• Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance

  2020cites this paper
• Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo

  2020cites this paper
• Extensive functional evaluation of exon 20 insertion mutations of EGFR.

  2020cites this paper
• Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis

  2020cites this paper
• Epidermal growth factor receptor (EGFR) involvement in epithelial‐derived cancers and its current antibody‐based immunotherapies

  2020cites this paper
• Targeting alveolar macrophages shows better treatment response than deletion of interstitial macrophages in EGFR mutant lung adenocarcinoma

  2020influential citation
• Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

  2020cites this paper
• Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis

  2020cites this paper
• Approach to the Subsolid Nodule.

  2020cites this paper
• Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer

  2020cites this paper